These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 31779056)

  • 1. Evaluation of Waning Immunity at 6 Months after Both Trivalent and Quadrivalent Influenza Vaccination in Korean Children Aged 6-35 Months.
    Lee JH; Cho HK; Kim KH; Lee J; Kim YJ; Eun BW; Kim NH; Kim DH; Jo DS; Kim HM; Kim YK
    J Korean Med Sci; 2019 Dec; 34(46):e279. PubMed ID: 31779056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y; Kimachi K; Okada Y; Matsuura K; Ooyama Y; Ibaragi K; Kino Y; Ueda K
    Microbiol Immunol; 2015 Oct; 59(10):597-604. PubMed ID: 26272602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Immunogenicity of an Egg-Cultivated Quadrivalent Inactivated Split-virion Influenza Vaccine (GC3110A) in Healthy Korean Children: a Randomized, Double-blinded, Active-controlled Phase III Study.
    Lee J; Lee KY; Kim JH; Kim CS; Eun BW; Kim HM; Kim DH; Hong YJ; Choi YY; Jo DS; Ma SH; Kang JH
    J Korean Med Sci; 2018 Mar; 33(13):e100. PubMed ID: 29573247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of Quadrivalent Influenza HA vaccine in Indonesian children: An open-labeled, bridging, clinical study.
    Dhamayanti M; Tarigan R; Fadlyana E; Prasetyo D; Amalia N; Rusmil VK; Sari RM; Bachtiar NS; Rusmil K; Kartasasmita CB
    Vaccine; 2020 Jan; 38(5):993-1000. PubMed ID: 31862195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D; Sheldon E; Lin WY; Yu CJ; Bayas JM; Gabor JJ; Esen M; Fernandez Roure JL; Narejos Perez S; Alvarez Sanchez C; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    BMC Infect Dis; 2013 Jul; 13():343. PubMed ID: 23883186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in children 6-59 months of age: A phase 3, randomized, noninferiority study.
    Statler VA; Albano FR; Airey J; Sawlwin DC; Graves Jones A; Matassa V; Heijnen E; Edelman J; Marshall GS
    Vaccine; 2019 Jan; 37(2):343-351. PubMed ID: 30057283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M; Dubiel P; Drozd-Dąbrowska M; Hallmann-Szelińska E; Szymański K; Brydak LB
    Int J Environ Res Public Health; 2019 Nov; 16(22):. PubMed ID: 31739554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological persistence of a seasonal influenza vaccine in people more than 3 years old.
    Bai Y; Shi N; Lu Q; Yang L; Wang Z; Li L; Han H; Zheng D; Luo F; Zhang Z; Ai X
    Hum Vaccin Immunother; 2015; 11(7):1648-53. PubMed ID: 26083828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial.
    Sesay S; Brzostek J; Meyer I; Donazzolo Y; Leroux-Roels G; Rouzier R; Astruc B; Szymanski H; Toursarkissian N; Vandermeulen C; Kowalska E; Van Damme P; Salamand C; Pepin S
    Hum Vaccin Immunother; 2018 Mar; 14(3):596-608. PubMed ID: 28968138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.
    Zerbini CA; Ribeiro Dos Santos R; Jose Nunes M; Soni J; Li P; Jain VK; Ofori-Anyinam O
    Braz J Infect Dis; 2017; 21(1):63-70. PubMed ID: 27912069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS; Noh JY; Song JY; Cheong HJ; Wie SH; Lee JS; Lee J; Kim SW; Jeong HW; Jung SI; Kim YS; Woo HJ; Kim KH; Kim H; Kim WJ
    Hum Vaccin Immunother; 2017 Jul; 13(7):1653-1660. PubMed ID: 28406746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a quadrivalent inactivated influenza virus vaccine compared with a comparator quadrivalent inactivated influenza vaccine in a pediatric population: A phase 3, randomized noninferiority study.
    Airey J; Albano FR; Sawlwin DC; Jones AG; Formica N; Matassa V; Leong J
    Vaccine; 2017 May; 35(20):2745-2752. PubMed ID: 28390934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, single-blind, active-controlled phase I clinical trial to evaluate the immunogenicity and safety of GC3114 (high-dose, quadrivalent influenza vaccine) in healthy adults.
    Noh JY; Jang YS; Lee SN; Choi MJ; Yoon JG; Yu DH; Song JY; Cheong HJ; Kim WJ
    Vaccine; 2019 Aug; 37(36):5171-5176. PubMed ID: 31377075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.